List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 20 studies with search of:   "Bendamustine"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine;   Drug: Rituximab
2 Recruiting Bendamustine in Acute Leukemia and MDS
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia
Intervention: Drug: Bendamustine
3 Active, not recruiting Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: bortezomib;   Drug: bendamustine;   Drug: rituximab
4 Active, not recruiting A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Bendamustine
5 Recruiting Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Conditions: Hodgkin's Disease;   Lymphoma
Intervention: Drug: bendamustine hcl
6 Recruiting Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
7 Active, not recruiting SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bendamustine and rituximab
8 Active, not recruiting Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Bendamustine HCl
9 Recruiting A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: VELCADE, bendamustine and rituximab
10 Completed Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: SDX-105
11 Active, not recruiting Bendamustine and Bortezomib Combination Therapy in Indolent NHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Bendamustine;   Drug: Bortezomib
12 Active, not recruiting Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Drug: bendamustine hydrochloride;   Drug: mitoxantrone hydrochloride
13 Recruiting Bendamustine and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Drug: bendamustine hydrochloride;   Drug: rituximab
14 Recruiting Fludarabine, Cyclophosphamide, and Rituximab or Bendamustine and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Drug: bendamustine hydrochloride;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: rituximab
15 Completed A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bendamustine hydrochloride
16 Completed Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
Condition: Sarcoma, Soft Tissue
Intervention: Drug: Bendamustin
17 Active, not recruiting Phase II Clinical Study on SyB L-0501 in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
18 Recruiting Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Condition: Lymphoma, High-Grade
Interventions: Drug: Bendamustine;   Drug: Rituximab
19 Recruiting A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma
Interventions: Drug: SyB L-0501;   Drug: Rituximab
20 Recruiting Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Conditions: Cancer-Related Problem/Condition;   Leukemia
Interventions: Drug: alemtuzumab;   Procedure: flow cytometry;   Procedure: laboratory biomarker analysis;   Procedure: pharmacological study;   Procedure: polymerase chain reaction

  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services